Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...
BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ...
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, tod...
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, toda...
Shares of micro-cap clinical-stage biotech Pieris Pharmaceuticals ( NASDAQ: PIRS ) have lost 7.4% to $1.69 in Thursday mid-day trading, after the company reported Q2 results that missed estimates and said it would discontinue a phase 2 trial. PIRS posted Q2 GAAP EP...
Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q2 GAAP EPS of -$0.14 misses by $0.03 . Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M . Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and ...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing ga...
Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.20 (+20.0% Y/Y) and the consensus Revenue Estimate is $10.47M (+218.2% Y/Y). Over the last 3 months, EPS ...
ABMD , ABUS , ACIW , ADAP , OTCQX:ADDYY , ADT , AG , AGIO , AHH , APD , APO , APTV , ARW , ATI , AUPH , AUTL , AZEK , BABA , BALL , BALY , OTCPK:BAYZF , BCE , BCRX , BDX , BKI , CBRE , ...
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ann...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-04-23 09:02:03 ET Pieris Pharmaceuticals Inc (PIRS) announced stock split at a ratio of 1-for-80 on 2024-04-23 ... Full story available on KlickAnalytics.com